DEFERIPRONE (deferiprone) by Hikma is iron chelating activity [moa]. Approved for transfusional iron overload in adult patients with thalassemia syndromes, anemia. First approved in 2019.
Drug data last refreshed 18h ago
Iron Chelating Activity
Iron Chelator
Worked on DEFERIPRONE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Study of Parkinson's Early Stage With Deferiprone
Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent